| |
| |
SPOT ON
|
| |
Publication bias: studies with negative results often remain unpublished
|
| |
| |
NEW ON THE MARKET
|
| |
Nadifloxacin (NADIXA) for acne
Alopecia: what's the benefit of external minoxidil for women
|
| |
| |
THERAPIES FROM A CRITICAL VIEW POINT
|
 |
Angiotensin converting enzyme inhibitors for patients with type 2 diabetes and albuminuria |
| |
| |
a-t READERS' QUESTIONS AND COMMENTS
|
| |
Metformin: to be discontinued before surgery?
Carcinogenic potential of insulin analogues
Naltrexone and/or acamprosate in the treatment of alcohol dependence
Vasopressin (PITRESSSIN) off market
About the pricing of transdermal buprenorphine (TRANSTEC)
|
| |
| |
IN BRIEF
|
| |
Again: escitalopram is not better than citalopram
Calcium channel blocker amlodipine now as generics available
Herpes genitalis: long-term therapy reduces transmission rate
Autologous tumor cell vaccine for renal-cell carcinoma
Estrogen monotherapy increases risk for stroke
Manual versus powered toothbrushing
Humidifier cannot be recommended for doctor`s practice
|
| |
| |
CURRENT ADR NETWORK REPORT
|
| |
Hypersexuality under dopamine agonist Pramipexole
|
| |
| |
SIDE EFFECTS
|
| |
Dementia: olanzapine (ZYPREXA) increases mortality
|
| |